chronic pain treatment News
-
Meagan Medical Inc. Announces Issuance of a Key U.S. Patent for a Disruptive Chronic Pain Treatment using Spinal Cord Stimulation
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
-
Nevro to Present at Citi`s 2022 Virtual Healthcare Conference
REDWOOD CITY, Calif., Jan. 31, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman, Nevro's Chairman, CEO and President, will present at Citi's 2022 Virtual Healthcare Conference on Thursday, February 24, 2022 at 12:30 pm Eastern ...
By Nevro Corp.
-
Publication of Two-Year EVOKE Double-Blind Randomized Controlled Trial Results in JAMA Neurology Demonstrate Sustained Superiority of Evoke® Closed-Loop over Open-Loop Spinal Cord Stimulation
Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced long-term results of its double-blind Level 1 EVOKE randomized controlled trial (RCT) published online in ...
-
Nevro to Report Fourth Quarter and Full-Year 2021 Financial Results
Company to Host Conference Call on Wednesday, February 23, 2022 at 1:30 pm PT / 4:30 pm ET. REDWOOD CITY, Calif., Jan. 24, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that the company will report its financial results for the fourth quarter and full-year ...
By Nevro Corp.
-
Nevro Named to 2022 Bloomberg Gender-Equality Index
Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies. REDWOOD CITY, Calif., Jan. 26, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has been named to the 2022 Bloomberg Gender-Equality Index (GEI). The ...
By Nevro Corp.
-
Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2021 Revenue
Fourth Quarter 2021 Worldwide Revenue of Approximately $102.5 Million. Full-Year 2021 Worldwide Revenue of Approximately $386.6 Million Company Expects to Exceed High End of Previously Provided Fourth Quarter 2021 Non-GAAP Adjusted EBITDA Guidance Company to Present Today at J.P. Morgan Healthcare Conference at 4:30 pm Eastern Time. REDWOOD CITY, Calif., Jan. 10, 2022 /PRNewswire/ -- Nevro Corp. ...
By Nevro Corp.
-
NBC News’ TODAY Features the Minimally Invasive Intracept® Procedure for Chronic Vertebrogenic Low Back Pain
Relievant Medsystems shared today that the company’s breakthrough chronic low back pain treatment, the Intracept Procedure, was featured on NBC’s TODAY this morning. The full segment can be viewed here. “This is an exciting story, not only for the patients I’ve treated, but also for the millions of patients with chronic vertebrogenic low back pain who will now learn about ...
-
Nevro Announces UnitedHealthcare Coverage for High-Frequency 10 kHz Therapy for the Treatment of Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Jan. 4, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that UnitedHealthcare, the largest private health insurance company in the United States, will provide coverage for the company's high-frequency 10 kHz Therapy for the treatment of ...
By Nevro Corp.
-
Nalu Micro-Implantable Pulse Generator Receives Expanded FDA Label for Service Life of 18 Years
Nalu Medical, Inc. (“Nalu”), a California-based company that has successfully miniaturized neurostimulation implants for the treatment of chronic pain via Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS), in July 2020 received clearance from the U.S. Food and Drug Administration (FDA) of an expanded label for its micro-Implantable Pulse Generator (mIPG) to an ...
-
Nevro Announces FDA Approval for Expanded Labeling for its 10 kHz High Frequency Spinal Cord Stimulation System for Treatment of Non-Surgical Refractory Back Pain (NSRBP)
REDWOOD CITY, Calif., Jan. 19, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced receipt of FDA approval for expanded labeling for its Senza® Spinal Cord Stimulation (SCS) System for the treatment of Non-Surgical Refractory Back Pain (NSRBP). This approval ...
By Nevro Corp.
-
Gelmetix closes successful £5 million capital raise, progresses to first-in-human trial
Medtech start-up Gelmetix, the developer of a first-in-class polymer treatment for chronic lower back pain, has closed a successful £5 million Series C equity financing round. Following successful in-vivo and pre-clinical studies, the University of Manchester spin-out will now use the additional capital to fund its upcoming first-in-human (FIH) trial and preparing for the pivotal study. ...
-
Clinical Data Presented at 2022 North American Neuromodulation Society (NANS) Annual Meeting Reinforce Significant and Durable Benefits of Nevro`s 10 kHz Therapy
SENZA-PDN Randomized Controlled Trial Results Demonstrate Significant and Sustained Outcomes with 10 kHz Therapy at 18-Months Follow-Up. SENZA-NSRBP Randomized Controlled Trial Results Show Profound Improvements in Non-Surgical Refractory Back Pain Patients Receiving 10 kHz Therapy Relative to Conventional Medical Management at 12-Months Follow-Up. Both SENZA-PDN and SENZA-NSRBP Studies ...
By Nevro Corp.
-
Nevro Responds to Competitor`s Announcement of FDA Approval for Painful Diabetic Neuropathy
REDWOOD CITY, Calif., Jan. 25, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today responded to Medtronic's announcement of FDA approval for painful diabetic neuropathy (PDN). "PDN represents a very large potential market, and having another competitor validate this large ...
By Nevro Corp.
-
Robotic innovation delivers relief for back pain sufferers
An innovation that automates the diagnosis and treatment of chronic back pain could bring benefits to millions of patients, increase work productivity and provide therapists with a time-saving ...
By Adamo Robot
-
Physiotherapy for back pain with a contactless AI robot - Spain Adamo Robot
The protocol for the treatment of chronic back pain is difficult to establish, but certain results of physical therapy are expected. A fully automated physical therapy robot has been developed to promote the use of physical therapy and improve the productivity of physical ...
By Adamo Robot
-
The European Medicines Agency accepts application to extend the Buvidal indication to include treatment of chronic pain
Camurus (NASDAQ STO: CAMX) today announces that the European Medicines Agency (EMA) has accepted the company’s submission of a Type II variation application for Buvidal (buprenorphine) prolonged release injection to include treatment of chronic pain. “We are pleased that the review procedure has been initiated. There is a high unmet medical need in chronic pain, particularly among ...
By Camurus AB
-
Gelmetix 3rd in prestigious EIT Health Catapult competition
We’re delighted to announce that on 3rd December, with total prize winnings of €210,000 available among the best performers. The seven finalists represented best-in-class innovations in biotech across Europe, having been selected from hundreds of entrants. EIT Health Catapult is a unique competition and training programme that showcases biotech, medtech and digital health start-ups ...
-
Gelexir becomes Gelmetix
We are proud to announce that our rebranding process is now complete. Gelexir Healthcare, known for being a spin off of the University of Manchester and for its cutting edge R&D work on non-invasive treatments for Chronic Low Pain, officially becomes Gelmetix. This rebranding process has been developed in line with our new multi-product strategy, focused on three large unmet medical needs: ...
-
Clinical Data Presented at 2021 North American Neuromodulation Society (NANS) Virtual Meeting Reinforce Significant Benefits of Nevro`s HF10® Therapy
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the results from data presentations at NANS supporting the use of HF10® therapy for patients with chronic pain, including results from the Painful Diabetic Neuropathy (PDN) and Non-Surgical Refractory Back Pain (NSRBP) randomized ...
By Nevro Corp.
-
Nalu and Nevro Reach Settlement in Patent Infringement Lawsuit
Nalu Medical, Inc. announced today that Nalu and Nevro Corporation have reached a settlement in the patent infringement lawsuit brought by Nevro in February 2020. “We are very pleased that we are able to put this litigation behind us, while maintaining our current menu of therapy options,” said Earl Fender, CEO. Nalu is a California-based company with miniaturized, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you